Ahn, E. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Calfa, C. J., Alva, A. S., … Schilsky, R. L. (2024). Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, (8). https://doi.org/10.1200/po.23.00240

Ahn, Eugene R., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Carmen J. Calfa, Ajjai S. Alva, Vijay Suhag, et al. “Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, no. 8 (February 2024). https://doi.org/10.1200/po.23.00240.

Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Calfa CJ, Alva AS, et al. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 2024 Feb;(8).

Ahn, Eugene R., et al. “Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, no. 8, American Society of Clinical Oncology (ASCO), Feb. 2024. Crossref, doi:10.1200/po.23.00240.

Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Calfa CJ, Alva AS, Suhag V, Alese OB, Dotan E, Hamid O, Yang ES, Marr AS, Palmer MC, Thompson FL, Yost KJ, Gregory A, Grantham GN, Hinshaw DC, Halabi S, Schilsky RL. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. American Society of Clinical Oncology (ASCO); 2024 Feb;(8).